{"id":22870,"date":"2017-04-10T13:04:04","date_gmt":"2017-04-10T13:04:04","guid":{"rendered":"https:\/\/corporate.webfactory.ferring.tech\/?p=22870"},"modified":"2021-05-10T18:10:18","modified_gmt":"2021-05-10T17:10:18","slug":"ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide","status":"publish","type":"post","link":"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/","title":{"rendered":"Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide"},"content":{"rendered":"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h2 style=\"color: #0088ce\">Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide<\/h2>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<p>Controlled-release treatments can maximise efficiency and improve patient-adherence<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce\">Saint Prex, Switzerland \u2013\u00a010 April, 2017 \u2013<\/h3>\n<p>Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with exclusive option rights for Ferring to leverage Alrise\u2019s\u00a0<em>ImSus<\/em>\u00ae Technology Platform for the development of an injectable, controlled-release formulation of a peptide therapeutic.<\/p>\n<p>Under the terms of the agreement, Alrise will conduct feasibility and scale-up studies with Ferring. Upon completion of the development work, Ferring will have the right to exercise its option and enter into a definitive agreement with Alrise to further develop and manufacture the formulation.<\/p>\n<p>\u201cFerring aims to harness innovative technology platforms, such as Alrise\u2019s microparticle-technology platform, in order to provide new, controlled-release formulations of peptides and proteins for our patients,\u201d said Alan S. Harris, Senior Vice President, R&amp;D Executive Office, Ferring Pharmaceuticals. \u201cControlled, long-duration release treatments can maximise efficiency, help improve compliance to treatment, and make life simpler for our patients.\u201d<\/p>\n<p>\u201cAlrise is committed to delivering solutions that enhance the performance of drug products in development,\u201d said Volker Rindler, Head of Business Development and Co-Founder, Alrise Biosystems. \u201cTogether with Ferring we aim to develop a new depot formulation that, once injected, releases the drug in a controlled way and thereby ensures an effective drug level over several months.\u201d<\/p>\n<p>Ferring recently announced a number of agreements aimed at developing new formulations of peptide-based therapeutics through novel technology platforms, including a\u00a0<a title=\"Ferring Pharmaceuticals and Ach\u00e9 Laborat\u00f3rios Farmac\u00eauticos collaborate on nanotechnology R&amp;D platform\" href=\"https:\/\/www.ferring.com\/en\/media\/press-releases\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/#\">long-term collaboration with Ach\u00e9 Laborat\u00f3rios Farmac\u00eauticos<\/a>, aimed at improving the bioavailability, efficacy and safety profile of oral therapeutic medicines through nanotechnology.<\/p>\n<p>&#8211; ENDS &#8211;<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce\">About ImSus\u00ae Technology Platform<\/h3>\n<p><em>ImSus<\/em>\u00ae is a unique drug delivery technology platform for the design and manufacture of drug-loaded polymeric nano- and microparticle formulations. The patented process allows an efficient encapsulation of small molecule, peptide and protein drugs for injectable controlled release applications. Key advantages of the\u00a0<em>ImSus<\/em>\u00ae technology include the exclusive use of non-harmful (non-carcinogenic) organic solvents and\u00a0 the control over critical performance attributes, which aim to shorten product development times and lower costs.<\/p>\n<h3 style=\"color: #0088ce\">About Ferring Pharmaceuticals<\/h3>\n<p>Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.<\/p>\n<p>To learn more about Ferring or its products please visit <a href=\"https:\/\/www.ferring.com\/\">www.ferring.com<\/a>.<\/p>\n<h3 style=\"color: #0088ce\">About ALRISE Biosystems<\/h3>\n<p>Alrise was founded in 2004 by Dr. Celal Albayrak, Dr. Volker Rindler and Dr. Heiko Seemann. In collaboration with pharmaceutical companies Alrise develops injectable as well as oral formulations based on polymeric nano- and microparticles for various substance classes. Major shareholders in the Berlin-based company are the VC companies Creathor Venture and IBB Beteiligungsgesellschaft mbH as well as Dr. Giuseppe Vita, the former CEO of Schering AG.<\/p>\n<p>For more information visit <a href=\"http:\/\/www.alrise.de\/\">www.alrise.de<\/a>.<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce\">For more information, please contact<\/h3>\n<p>Ferring Pharmaceuticals<br \/>\n<strong>Lindsey Rodger<\/strong><br \/>\nTel. +41 58 451 40 23<br \/>\n<a href=\"mailto:lindsey.rodger@ferring.com\">lindsey.rodger@ferring.com<\/a><\/p>\n<p>ALRISE Biosystems GmbH<br \/>\n<strong>Dr. Volker Rindler<\/strong><br \/>\nTel. +49 30 94 89 24 85<br \/>\n<a href=\"mailto:rindler@alrise.de\">rindler@alrise.de<\/a><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_row element_name=&#8221;Row&#8221; wrap_type=&#8221;content-width&#8221; parallax_image_height=&#8221;content-height&#8221; parallax_image_movement=&#8221;fixed&#8221; parallax_image_speed=&#8221;0.5&#8243; bg_video_loop=&#8221;yes&#8221; parallax_video_height=&#8221;window-height&#8221; parallax_video_overlay=&#8221;none&#8221; row_overlay_opacity=&#8221;0&#8243; row_col_pos=&#8221;default&#8221; minimize_row=&#8221;no&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_button button_text=&#8221;READ MORE PRESS RELEASES&#8221; button_size=&#8221;standard&#8221; button_colour=&#8221;accent&#8221; button_type=&#8221;standard&#8221; rounded=&#8221;no&#8221; button_dropshadow=&#8221;no&#8221; button_link=&#8221;\/media\/press-releases\/&#8221; button_target=&#8221;_self&#8221; align=&#8221;center&#8221; animation=&#8221;none&#8221; animation_delay=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [\/spb_row]\n","protected":false},"excerpt":{"rendered":"<p>[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Controlled-release treatments can maximise efficiency and improve patient-adherence [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Saint [&hellip;]<\/p>\n","protected":false},"author":2410,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[244],"tags":[],"class_list":["post-22870","post","type-post","status-publish","format-standard","hentry","category-press-release-2017"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.3 (Yoast SEO v23.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide - Ferring Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide\" \/>\n<meta property=\"og:description\" content=\"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Controlled-release treatments can maximise efficiency and improve patient-adherence [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Saint [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/\" \/>\n<meta property=\"og:site_name\" content=\"Ferring Global\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-10T13:04:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-10T17:10:18+00:00\" \/>\n<meta name=\"author\" content=\"pulse\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ferring\" \/>\n<meta name=\"twitter:site\" content=\"@ferring\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"pulse\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/\"},\"author\":{\"name\":\"pulse\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d\"},\"headline\":\"Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide\",\"datePublished\":\"2017-04-10T13:04:04+00:00\",\"dateModified\":\"2021-05-10T17:10:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/\"},\"wordCount\":805,\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"articleSection\":[\"PRESS RELEASE 2017\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/\",\"url\":\"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/\",\"name\":\"Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide - Ferring Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/#website\"},\"datePublished\":\"2017-04-10T13:04:04+00:00\",\"dateModified\":\"2021-05-10T17:10:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ferring.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ferring.com\/#website\",\"url\":\"https:\/\/www.ferring.com\/\",\"name\":\"Ferring Pharmaceuticals\",\"description\":\"Helping people live better lives\",\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ferring.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ferring.com\/#organization\",\"name\":\"Ferring\",\"url\":\"https:\/\/www.ferring.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"contentUrl\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"width\":236,\"height\":154,\"caption\":\"Ferring\"},\"image\":{\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\",\"https:\/\/x.com\/ferring\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d\",\"name\":\"pulse\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g\",\"caption\":\"pulse\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide - Ferring Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/","og_locale":"en_US","og_type":"article","og_title":"Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide","og_description":"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Controlled-release treatments can maximise efficiency and improve patient-adherence [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Saint [&hellip;]","og_url":"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/","og_site_name":"Ferring Global","article_publisher":"https:\/\/www.facebook.com\/ferringpharmaceuticals\/","article_published_time":"2017-04-10T13:04:04+00:00","article_modified_time":"2021-05-10T17:10:18+00:00","author":"pulse","twitter_card":"summary_large_image","twitter_creator":"@ferring","twitter_site":"@ferring","twitter_misc":{"Written by":"pulse","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/#article","isPartOf":{"@id":"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/"},"author":{"name":"pulse","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d"},"headline":"Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide","datePublished":"2017-04-10T13:04:04+00:00","dateModified":"2021-05-10T17:10:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/"},"wordCount":805,"publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"articleSection":["PRESS RELEASE 2017"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/","url":"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/","name":"Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide - Ferring Global","isPartOf":{"@id":"https:\/\/www.ferring.com\/#website"},"datePublished":"2017-04-10T13:04:04+00:00","dateModified":"2021-05-10T17:10:18+00:00","breadcrumb":{"@id":"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ferring.com\/ferring-announces-exclusive-agreement-with-alrise-biosystems-for-the-development-of-an-injectable-controlled-release-peptide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ferring.com\/"},{"@type":"ListItem","position":2,"name":"Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide"}]},{"@type":"WebSite","@id":"https:\/\/www.ferring.com\/#website","url":"https:\/\/www.ferring.com\/","name":"Ferring Pharmaceuticals","description":"Helping people live better lives","publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ferring.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ferring.com\/#organization","name":"Ferring","url":"https:\/\/www.ferring.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/","url":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","contentUrl":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","width":236,"height":154,"caption":"Ferring"},"image":{"@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ferringpharmaceuticals\/","https:\/\/x.com\/ferring"]},{"@type":"Person","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d","name":"pulse","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g","caption":"pulse"}}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/22870"}],"collection":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/users\/2410"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/comments?post=22870"}],"version-history":[{"count":0,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/22870\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/media?parent=22870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/categories?post=22870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/tags?post=22870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}